Methylation of gene promoter in the prediction of concurrent chemo-radiotherapy efficacy in cervical cancer.

Cervical cancer is the fourth leading cause of cancer death among women worldwide. In currently, aberrant methylation of is found in variety of solid tumors, including cervical cancer. In addition, the role of gene methylation in cervical cancer and precancerous lesions screening has been confirmed in previous study. Here, we evaluated the predictive value of methylation in concurrent chemo-radiotherapy (CCRT) outcomes in cervical cancer. This study enrolled 82 cervical cancer patients from August 2018 to August 2020. We compared the clinical results between different methylation status. Hyper-methylation patients were subjects to MRI and quantitative methylation-specific PCR (QMSP) for before, in the middle, immediately after, 1 month and 3 months after CCRT. The changes in methylation during CCRT were analyzed. The lower methylation status were related to a poor tumor response. Based on the MRI findings three months post-treatment, the hypermethylated patients were classified into the complete response (CR; n=50) and partial remission (PR; n=18) groups. The average △Cp value of CR and PR groups before radiotherapy was 5.08±1.98 and 4.32±2.00 respectively, and after concurrent chemo-radiotherapy was significantly increased to 17.35±4.96 and 16.99±6.17, respectively (P<0.05). Furthermore, the △Cp value between CR and PR groups were significantly different at mid-treatment and performed well in predicting short-term efficacy (AUC 0.84) in this period, and its sensitivity and specificity for predicting PR were 0.72 and 0.88, respectively. The methylation level may predict the sensitivity and efficacy of CCRT in cervical cancer.